Treatment of HIV infections and AIDS with protease inhibitor and two nucleoside analogs
Until December 31st 1997, 163 HIV/AIDS patients were treated with HAART at the Department of Infectious Diseases, Aarhus University Hospital. The patients mainly received a combination of zidovudine, lamivudine and saquinavir. They were observed for an average period of 375 days. HAART was found to increase the amount of CD4 lymphocytes in peripheral blood and decrease the number of HIV-RNA copies. Both effects were seen to be more pronounced in patients naive to antiretroviral treatment. However, 64 patients had their protease inhibitor changed during the observation period, 53% due to failure of suppression of the viral load, 25% due to adverse events and 22% due to other reasons.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
1999 |
|---|---|
| Erschienen: |
1999 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:161 |
|---|---|
| Enthalten in: |
Ugeskrift for laeger - 161(1999), 12 vom: 22. März, Seite 1751-4 |
| Sprache: |
Dänisch |
|---|
| Weiterer Titel: |
Behandling af HIV- og AIDS-patienter med proteaseinhibitor og to nukleosidanaloger |
|---|
| Beteiligte Personen: |
Jensen-Fangel, S [VerfasserIn] |
|---|
| Themen: |
5W6YA9PKKH |
|---|
| Anmerkungen: |
Date Completed 29.04.1999 Date Revised 21.11.2013 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM101437552 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM101437552 | ||
| 003 | DE-627 | ||
| 005 | 20231222122238.0 | ||
| 007 | tu | ||
| 008 | 231222s1999 xx ||||| 00| ||dan c | ||
| 028 | 5 | 2 | |a pubmed24n0339.xml |
| 035 | |a (DE-627)NLM101437552 | ||
| 035 | |a (NLM)10210974 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a dan | ||
| 100 | 1 | |a Jensen-Fangel, S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Treatment of HIV infections and AIDS with protease inhibitor and two nucleoside analogs |
| 246 | 3 | 3 | |a Behandling af HIV- og AIDS-patienter med proteaseinhibitor og to nukleosidanaloger |
| 264 | 1 | |c 1999 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 29.04.1999 | ||
| 500 | |a Date Revised 21.11.2013 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Until December 31st 1997, 163 HIV/AIDS patients were treated with HAART at the Department of Infectious Diseases, Aarhus University Hospital. The patients mainly received a combination of zidovudine, lamivudine and saquinavir. They were observed for an average period of 375 days. HAART was found to increase the amount of CD4 lymphocytes in peripheral blood and decrease the number of HIV-RNA copies. Both effects were seen to be more pronounced in patients naive to antiretroviral treatment. However, 64 patients had their protease inhibitor changed during the observation period, 53% due to failure of suppression of the viral load, 25% due to adverse events and 22% due to other reasons | ||
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a Controlled Clinical Trial | |
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Anti-HIV Agents |2 NLM | |
| 650 | 7 | |a HIV Protease Inhibitors |2 NLM | |
| 650 | 7 | |a Indinavir |2 NLM | |
| 650 | 7 | |a 5W6YA9PKKH |2 NLM | |
| 650 | 7 | |a Saquinavir |2 NLM | |
| 650 | 7 | |a L3JE09KZ2F |2 NLM | |
| 650 | 7 | |a Ritonavir |2 NLM | |
| 650 | 7 | |a O3J8G9O825 |2 NLM | |
| 700 | 1 | |a Larsen, L |e verfasserin |4 aut | |
| 700 | 1 | |a Thomsen, H F |e verfasserin |4 aut | |
| 700 | 1 | |a Nielsen, L P |e verfasserin |4 aut | |
| 700 | 1 | |a Black, F T |e verfasserin |4 aut | |
| 700 | 1 | |a Obel, N |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Ugeskrift for laeger |d 1945 |g 161(1999), 12 vom: 22. März, Seite 1751-4 |w (DE-627)NLM000011185 |x 1603-6824 |7 nnns |
| 773 | 1 | 8 | |g volume:161 |g year:1999 |g number:12 |g day:22 |g month:03 |g pages:1751-4 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 161 |j 1999 |e 12 |b 22 |c 03 |h 1751-4 | ||